公开(公告)号：US20070082907A1

公开(公告)日：2007-04-12

申请号：US10579028

申请日：2004-11-16

Applicant: Emily Canada ,  Lynn Gossett ,  Nathan Mantlo ,  Qing Shi ,  Minmin Wang ,  Alan Warshawsky ,  Yanping Xu

Inventor： Emily Canada ,  Lynn Gossett ,  Nathan Mantlo ,  Qing Shi ,  Minmin Wang ,  Alan Warshawsky ,  Yanping Xu

IPC: A61K31/4245 ,  A61K31/53 ,  A61K31/515 ,  A61K31/4709 ,  A61K31/427 ,  A61K31/4178 ,  C07D417/02 ,  C07D413/02 ,  C07D403/02

CPC classification number: C07D213/81 ,  C07C211/29 ,  C07C233/73 ,  C07C235/46 ,  C07C235/48 ,  C07C235/54 ,  C07C235/84 ,  C07C271/16 ,  C07C311/04 ,  C07C311/17 ,  C07C317/44 ,  C07C323/62 ,  C07D209/30 ,  C07D209/42 ,  C07D213/56 ,  C07D333/70

Abstract: The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，溶剂合物水合物或立体异构体，其可用于治疗或预防由过氧化物酶体增殖物激活受体（PPAR）介导的病症，例如综合征X型 II型糖尿病，高血糖症，高脂血症，肥胖症，凝血病，高血压，动脉硬化以及与X综合症和心血管疾病有关的其他疾病。

公开(公告)号：US20070037812A1

公开(公告)日：2007-02-15

申请号：US10571961

申请日：2004-10-08

Applicant: Leonard Winneroski ,  Yanping Xu ,  Jeremy York

Inventor： Leonard Winneroski ,  Yanping Xu ,  Jeremy York

IPC: A61K31/53 ,  A61K31/513 ,  A61K31/426 ,  A61K31/4245 ,  A61K31/42 ,  A61K31/4166

CPC classification number: C07D213/30 ,  C07C59/68 ,  C07C59/70 ,  C07C59/90 ,  C07C317/22 ,  C07C323/52 ,  C07D213/64 ,  C07D213/643 ,  C07D213/69 ,  C07D239/26

Abstract: The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR), such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，溶剂合物，水合物或立体异构体，其可用于治疗或预防由过氧化物酶体增殖物激活受体（PPAR）介导的病症，例如综合征X ，II型糖尿病，高血糖症，高脂血症，肥胖症，凝血病，高血压，动脉硬化以及与X综合症和心血管疾病相关的其它疾病。

公开(公告)号：US20050020652A1

公开(公告)日：2005-01-27

申请号：US10496770

申请日：2002-11-26

Applicant: Tracey Gibson ,  Richard Johnston ,  Nathan Mantlo ,  Richard Thompson ,  Leonard Winneroski ,  Yanping Xu ,  Xiaodong Wang

Inventor： Tracey Gibson ,  Richard Johnston ,  Nathan Mantlo ,  Richard Thompson ,  Leonard Winneroski ,  Yanping Xu ,  Xiaodong Wang

IPC: A61K31/4174 ,  A61K31/443 ,  A61K31/4709 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P9/00 ,  A61P9/12 ,  A61P43/00 ,  C07D233/32 ,  C07D233/66 ,  C07D233/70 ,  C07D233/76 ,  C07D233/78 ,  C07D401/06 ,  C07D403/12 ,  C07D405/06 ,  C07D405/12 ,  A61K31/4178 ,  A61K31/4166

CPC classification number: C07D401/06 ,  C07D233/32 ,  C07D233/70 ,  C07D233/76 ,  C07D403/12 ,  C07D405/06 ,  C07D405/12

Abstract: The present invention is directed to compounds represented by the following structural Formula (I), (a) R1 is selected from the group consisting of hydrogen, substituted or unsubstituted group selected from C1-C8 alkyl, aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, C6 cycloalkylaryl-C0-2-alkyl, and —CH2—C(O)—R17-R18, wherein R17 is O or NH and R18 is optionally substituted benzyl; (b) R2 is selected from the group consisting of C1-C6 alkyl, C1-C6 alkenyl, aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, C1-C4 alkyl sulfonamide, C1-C4 alkyl amide, OR10 and C3-C6 cycloalkyl; (c) W is O or S; (d) X is an optionally substituted C1-C5 alkylene linker wherein one carbon atom of the linker may optionally be replaced with O, NH, S, and optionally two carbons together may form a double bond; (e) Y is selected from the group consisting of C, O, S, NH and a single bond; and (f) E is selected from the group consisting of C(R3) (R4)A, A, and a substituted or unsubstituted group selected from the group consisting of (CH2)n COOR19.

Abstract translation: 本发明涉及由以下结构式（I）表示的化合物，（a）R 1选自氢，取代或未取代的选自C 1 -C 8烷基，芳基-C 0-4 - 烷基，杂芳基 -C 0-4 - 烷基，C6环烷基芳基-C0-2 - 烷基和-CH2-C（O）-R17-R18，其中R17是O或NH，R18是任选取代的苄基; （b）R 2选自C 1 -C 6烷基，C 1 -C 6烯基，芳基-C 0-4 - 烷基，杂芳基-C 0-4 - 烷基，C 1 -C 4烷基磺酰胺，C 1 -C 4烷基酰胺，OR 10 和C 3 -C 6环烷基; （c）W为O或S; （d）X是任选取代的C1-C5亚烷基连接体，其中连接体的一个碳原子可以任选地被O，NH，S取代，并且任选地两个碳可以一起形成双键; （e）Y选自C，O，S，NH和单键; 和（f）E选自C（R 3）（R 4）A，A和选自（CH 2）n COOR 19的取代或未取代的基团。